![First data showing overall survival benefit for PARPi maintenance for Ovarian Cancer – ACS Journal Cancer](https://oncodaily.com/pub/uploads/2023/12/GBtxZw1XcAAhhvU-e1703697641226.png)
Photo taken from ACS Journal Cancer/X
Dec 27, 2023, 13:21
First data showing overall survival benefit for PARPi maintenance for Ovarian Cancer – ACS Journal Cancer
ACS Journal Cancer posted on X/Twitter:
“Just published! ‘Top advances of the year: Ovarian Cancer’ by Dr. Melissa Lumish and Dr. William P. Tew of Team Ovary, Memorial Sloan Kettering Cancer Center.
Key updates:
- Mirvetuximab for PROC
- First data showing overall survival benefit for PARPi maintenance.”
Further reading.
Source: ACS Journal Cancer/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 31, 2024, 14:07